Ratings STAAR Surgical Company

Equities

STAA

US8523123052

Real-time Estimate Cboe BZX Other stock markets 11:38:35 2024-04-26 am EDT			5-day change	1st Jan Change
46.48 ^USD	-0.87%		+0.65%	+49.60%

Apr. 11	Mizuho Adjusts Price Target on STAAR Surgical to $53 From $45, Maintains Buy Rating	MT
Apr. 08	Canaccord Genuity Raises Price Target on STAAR Surgical to $46 From $32, Maintains Hold Rating	MT

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Thanks to a sound financial situation, the firm has significant leeway for investment.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Analyst opinion has improved significantly over the past four months.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 2605 times its estimated earnings per share for the ongoing year.
Based on current prices, the company has particularly high valuation levels.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The company is highly valued given the cash flows generated by its activity.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Revenue estimates are regularly revised downwards for the current and coming years.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
STAAR SURGICAL COMPANY	+49.60%	2.26B	B-
ABBOTT LABORATORIES	-2.48%	185B	C+
MEDTRONIC PLC	-3.97%	105B	C
BECTON, DICKINSON AND COMPANY	-5.25%	66.59B	A
DEXCOM, INC.	+3.23%	54.66B	B-
CENCORA, INC.	+16.59%	47.78B	B-
HOYA CORPORATION	+4.06%	41.26B	B+
WEST PHARMACEUTICAL SERVICES, INC.	+2.73%	26.95B	A-
METTLER-TOLEDO INTERNATIONAL, INC.	+3.01%	26.37B	B
TERUMO CORPORATION	+12.96%	24.8B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes